ES2097496T3 - Derivados acilaminoindol como agonistas de 5-ht1. - Google Patents
Derivados acilaminoindol como agonistas de 5-ht1.Info
- Publication number
- ES2097496T3 ES2097496T3 ES93907096T ES93907096T ES2097496T3 ES 2097496 T3 ES2097496 T3 ES 2097496T3 ES 93907096 T ES93907096 T ES 93907096T ES 93907096 T ES93907096 T ES 93907096T ES 2097496 T3 ES2097496 T3 ES 2097496T3
- Authority
- ES
- Spain
- Prior art keywords
- aryl
- alkyl
- alkylaryl
- hydrogen
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Materials For Photolithography (AREA)
- Soft Magnetic Materials (AREA)
- Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
COMPUESTOS DE FORMULA (I) DONDE N ES 0, 1 O 2; M ES 0 O 1; Y Y W SON CADA UNO UN RESIDUO AMINOACIDO; R1 ES HIDROGENO, ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6, ARILO, ALQUILARILO C1-C3, O ALQUILHETEROARILO C1-C3, Y -(CH2)PR3; R2 ES CF3, ALQUILO C1-C6, ARILO, ALQUILARILO C1-C3, Y -OR5; R3 ES CIANO, TRIFLUOROMETILO, O -OR4; R4 ES HIDROGENO, ALQUILO C1-C6, ALQUILARILO C1-C3, O ARILO; R5 ES ALQUILO C1-C6, ALQUILARILO C1-C3, O ARILO; R6 ES HIDROGENO, -OR7, O -NHCOR7; R7 ES HIDROGENO, ALQUILO C1 A C6, ARILO, O ALQUILO-ARILO C1 A C3; P ES 1,2, O 3; Y LOS GRUPOS ARILO ANTERIORES Y LAS FRACCIONES ARILO DE LOS GRUPOS ALQUILO-ARILO SON SELECCIONADOS INDEPENDIENTEMENTE DE FENILO Y FENILO SUSTITUIDO, EN DONDE DICHO FENILO SUSTITUIDO PUEDE SER SUSTITUIDO CON UNO A TRES GRUPOS SELECCIONADOS DE ALQUILO C1 A C4, HALOGENO, HIDROXI, CIANO, CARBOXIAMIDA, NITRO, Y ALCOXI C1 A C4 Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE ELLOS. ESTOS COMPUESTOS SE USAN EN TRATAMIENTO DE MIGRAÑA Y OTROS DESORDENES. ESTOSCOMPUESTOS SE USAN COMO PSICOTERAPEUTICOS Y SON POTENTES AGONISTAS (5-HT1) DE SEROTONINA Y SE PUEDEN USAR EN EL TRATAMIENTO DE DEPRESION, ANSIEDAD, DESORDENES ALIMENTARIOS, OBESIDAD, ABUSO DE DROGAS, CEFALEA EN RACIMO, MIGRAÑA, DOLOR, Y HEMICRANIA PAROXISMICA CRONICA Y CEFALEA ASOCIADA CON DESORDENES VASCULARES, Y OTROS DESORDENES SURGIDOS DE DEFICIENTE NEUROTRANSMISION SEROTONERGICA. LOS COMPUESTOS TAMBIEN PUEDEN SER USADOS COMO ANTIHIPERTENSIVOS Y VASODILATADORES QUE ACTUAN CENTRALMENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86638292A | 1992-04-10 | 1992-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2097496T3 true ES2097496T3 (es) | 1997-04-01 |
Family
ID=25347493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93907096T Expired - Lifetime ES2097496T3 (es) | 1992-04-10 | 1993-03-04 | Derivados acilaminoindol como agonistas de 5-ht1. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5498626A (es) |
| EP (1) | EP0635015B1 (es) |
| JP (1) | JP2544704B2 (es) |
| KR (1) | KR0179074B1 (es) |
| CN (1) | CN1038506C (es) |
| AT (1) | ATE148465T1 (es) |
| AU (1) | AU670270B2 (es) |
| BR (1) | BR9306221A (es) |
| CA (1) | CA2132706C (es) |
| CZ (1) | CZ282653B6 (es) |
| DE (1) | DE69307875T2 (es) |
| DK (1) | DK0635015T3 (es) |
| EG (1) | EG20466A (es) |
| ES (1) | ES2097496T3 (es) |
| FI (2) | FI111256B (es) |
| GR (1) | GR3022767T3 (es) |
| HR (1) | HRP930753B1 (es) |
| HU (1) | HUT64060A (es) |
| IL (1) | IL105309A0 (es) |
| MX (1) | MX9301996A (es) |
| MY (1) | MY115278A (es) |
| NO (1) | NO309860B1 (es) |
| NZ (1) | NZ251047A (es) |
| PL (1) | PL172232B1 (es) |
| RU (1) | RU2110516C1 (es) |
| SK (1) | SK278182B6 (es) |
| TW (1) | TW394769B (es) |
| UA (1) | UA34452C2 (es) |
| WO (1) | WO1993021180A1 (es) |
| YU (1) | YU48916B (es) |
| ZA (1) | ZA932536B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5559246A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| US5607951A (en) * | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| PL172405B1 (en) | 1992-04-07 | 1997-09-30 | Pfizer | Derivatives of indole |
| US6380233B1 (en) | 1992-04-07 | 2002-04-30 | Pfizer Inc | Indole derivatives as 5-HT1 agonists |
| ES2070772B1 (es) * | 1993-08-09 | 1996-02-16 | Pfizer | Derivados de acilaminoindol |
| EP0716649B1 (en) * | 1993-08-31 | 1998-09-09 | Pfizer Inc. | 5-arylindole derivatives |
| GB9402016D0 (en) * | 1994-02-02 | 1994-03-30 | Merck Sharp & Dohme | Therapeutic agents |
| GB9402011D0 (en) * | 1994-02-02 | 1994-03-30 | Merck Sharp & Dohme | Therapeutic agents |
| AU3162695A (en) * | 1994-08-03 | 1996-03-04 | Asta Medica Aktiengesellschaft | Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| GB9420503D0 (en) * | 1994-10-11 | 1994-11-23 | Pfizer Ltd | Therapeutic agents |
| GB9420529D0 (en) | 1994-10-12 | 1994-11-30 | Pfizer Ltd | Indoles |
| WO1999053956A1 (fr) * | 1998-04-16 | 1999-10-28 | Yamanouchi Pharmaceutical Co., Ltd. | Remedes contre l'obesite |
| US5994352A (en) * | 1998-11-13 | 1999-11-30 | Pfizer Inc. | 5-arylindole derivatives |
| US20050032750A1 (en) * | 2003-01-22 | 2005-02-10 | Steiner Mitchell S. | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS |
| CA2708043C (en) * | 2007-12-07 | 2012-11-13 | Pfizer Inc. | Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
| CN103408535B (zh) * | 2013-08-13 | 2016-03-02 | 张家港威胜生物医药有限公司 | 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
| CH652394A5 (fr) * | 1980-08-12 | 1985-11-15 | Glaxo Group Ltd | Derives indoliques, leur preparation et medicaments les renfermant. |
| ZA815541B (en) * | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
| GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
| GB8724912D0 (en) * | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| CA2042295A1 (fr) * | 1990-05-15 | 1991-11-16 | Jacques Chauveau | Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant |
| PL166214B1 (pl) * | 1990-06-07 | 1995-04-28 | Wellcome Found | Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL PL |
| ES2104733T3 (es) * | 1990-10-15 | 1997-10-16 | Pfizer | Derivados de indol. |
| US5208248A (en) * | 1991-01-11 | 1993-05-04 | Merck Sharpe & Dohme, Ltd. | Indazole-substituted five-membered heteroaromatic compounds |
| CZ283018B6 (cs) * | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi |
| UA41297C2 (uk) * | 1991-11-25 | 2001-09-17 | Пфайзер, Інк. | Похідні індолу, фармацевтична композиція і спосіб лікування |
-
1993
- 1993-03-04 RU RU94045902/04A patent/RU2110516C1/ru not_active IP Right Cessation
- 1993-03-04 NZ NZ251047A patent/NZ251047A/en unknown
- 1993-03-04 CA CA002132706A patent/CA2132706C/en not_active Expired - Fee Related
- 1993-03-04 DE DE69307875T patent/DE69307875T2/de not_active Expired - Fee Related
- 1993-03-04 KR KR1019940703551A patent/KR0179074B1/ko not_active IP Right Cessation
- 1993-03-04 JP JP5518302A patent/JP2544704B2/ja not_active Expired - Fee Related
- 1993-03-04 BR BR9306221A patent/BR9306221A/pt not_active Application Discontinuation
- 1993-03-04 DK DK93907096.7T patent/DK0635015T3/da active
- 1993-03-04 ES ES93907096T patent/ES2097496T3/es not_active Expired - Lifetime
- 1993-03-04 AT AT93907096T patent/ATE148465T1/de not_active IP Right Cessation
- 1993-03-04 SK SK1207-94A patent/SK278182B6/sk unknown
- 1993-03-04 AU AU37821/93A patent/AU670270B2/en not_active Ceased
- 1993-03-04 EP EP93907096A patent/EP0635015B1/en not_active Expired - Lifetime
- 1993-03-04 CZ CZ942477A patent/CZ282653B6/cs not_active IP Right Cessation
- 1993-03-04 WO PCT/US1993/001807 patent/WO1993021180A1/en active IP Right Grant
- 1993-03-04 UA UA94105907A patent/UA34452C2/uk unknown
- 1993-03-04 US US08/295,792 patent/US5498626A/en not_active Expired - Fee Related
- 1993-03-04 PL PL93305558A patent/PL172232B1/pl not_active IP Right Cessation
- 1993-03-09 TW TW082101732A patent/TW394769B/zh active
- 1993-04-02 HR HR930753A patent/HRP930753B1/xx not_active IP Right Cessation
- 1993-04-05 IL IL105309A patent/IL105309A0/xx not_active IP Right Cessation
- 1993-04-06 MX MX9301996A patent/MX9301996A/es unknown
- 1993-04-07 EG EG21493A patent/EG20466A/xx active
- 1993-04-08 MY MYPI93000646A patent/MY115278A/en unknown
- 1993-04-08 FI FI931613A patent/FI111256B/fi not_active IP Right Cessation
- 1993-04-08 ZA ZA932536A patent/ZA932536B/xx unknown
- 1993-04-09 HU HU9301048A patent/HUT64060A/hu unknown
- 1993-04-09 YU YU25593A patent/YU48916B/sh unknown
- 1993-04-09 CN CN93104439A patent/CN1038506C/zh not_active Expired - Fee Related
-
1994
- 1994-10-07 NO NO943803A patent/NO309860B1/no not_active IP Right Cessation
-
1997
- 1997-03-07 GR GR970400451T patent/GR3022767T3/el unknown
-
2001
- 2001-02-05 FI FI20010214A patent/FI20010214A/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2097496T3 (es) | Derivados acilaminoindol como agonistas de 5-ht1. | |
| MX9206762A (es) | Derivados de indol | |
| MY108909A (en) | Indole derivatives | |
| MY111683A (en) | Indole derivatives. | |
| KR960704843A (ko) | 5-아릴인돌 유도체 (5-arylindole derivatives) | |
| MY109298A (en) | Indole derivatives. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 635015 Country of ref document: ES |